Gilead Sciences' Phase 2B MYR204 Open-label Study Showed Bulevirtide Plus Pegylated Interferon Alfa-2A For Compensated Chronic Hepatitis Delta Virus Demonstrated Bulevirtide Combo Achieved Undetectable HDV RNA At Week 24 After The End Of Treatment
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences' Phase 2B MYR204 study showed promising results for Bulevirtide combined with Pegylated Interferon Alfa-2A in treating compensated chronic Hepatitis Delta Virus. 46% of patients achieved undetectable HDV RNA at week 24 post-treatment.
June 06, 2024 | 9:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences' Phase 2B MYR204 study showed promising results for Bulevirtide combined with Pegylated Interferon Alfa-2A in treating compensated chronic Hepatitis Delta Virus. 46% of patients achieved undetectable HDV RNA at week 24 post-treatment.
The positive results from the Phase 2B MYR204 study indicate a significant advancement in Gilead's treatment for chronic Hepatitis Delta Virus. This could lead to increased investor confidence and potential future revenue from the successful commercialization of the treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100